Financing channel feed – Endpoints News

Financing channel feed

Another four biotechs scratch out the first number and ask for more as IPO boom continues

5 years ago

Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts

5 years ago

A new venture fund amid a pandemic? In the Nordics? Eir Ventures brings it on with €76M first close

5 years ago

Nick Galakatos and the Blackstone team now have a record $4.6B to invest in biopharma, with a big focus on pushing companies over the top

5 years ago

Forbion spotlights late-stage plays, carves out new €250M growth fund

5 years ago

Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D

5 years ago

Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace

5 years ago

Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs

5 years ago

'Fundamentally different' from Portola, Dutch biotech lands €32M to steer anti-anticoagulant through the clinic

5 years ago

AlloVir tests how much an antiviral biotech can reap in a pandemic stock market

5 years ago

Investors give ailing Unum a lease on life and a whole new suite of experimental cancer drugs

5 years ago

RA Capital doubles down on Siddhartha Mukherjee's vision for a new cell engineering approach, leading Vor's $110M Series B

5 years ago

Pfizer re-ups on Mission Therapeutics collaboration, leading a $15M round and grabbing first dibs on DUBs

5 years ago

IPO bound? Actually, Annexon was already prepped and primed to toss its S-1 to Wall Street as investors rallied

5 years ago

IPO bound? A Bay Area biotech grabs a mega-round on the road to a pivotal neurodegeneration program

5 years ago

Bolt Biotherapeutics nabs $93.5M to push Provenge inventor's new idea deeper in the clinic

5 years ago

Armed with positive ALS data, Amylyx scores $30M in fresh funding to complete Alzheimer's PhII

5 years ago

Gilead-partnered Goldfinch Bio lands $100M as it pivots to clinical stage biotech

5 years ago

Takeda maps out a discovery alliance aimed at breaking through the safety and efficacy boundaries that limit the first-gen gene therapies

5 years ago

Freeline nabs $120M, eyes IPO as its gene therapy comes into focus

5 years ago

Pharma giants return to antibiotics huddle to launch $1B venture fund — report

5 years ago

The biotech IPO boom is becoming ‘historic’ as four more throw their hats in

5 years ago

Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO

5 years ago

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors

5 years ago

First page Previous page 95 96 979899 100 101 Next page Last page